Many companies start up “eClinical” projects. But what is eClinical – and how does it support the R&D strategy?
Many companies start up "eClinical" projects. But what is eClinical - and how does it support the R&D strategy? According to industry thought-leaders, defining it as EDC or ePRO misses the point. The break-through benefits lie in taking a holistic approach to the "R&D IT System": re-engineering R&D through coordinated development of the systems portfolio.
An eClinical program is a coordinated portfolio of projects, each with the purpose of optimising R&D processes, supported by IT systems such as: Clinical Trial Management System (CTMS), Electronic Data Capture (EDC), Clinical Data Management System (CDMS), Clinical Data Warehouse (CDW), Safety System, Product Supply, Interactive Voice Response System (IVRS), and Resource and Portfolio Management System.
These systems are typical components in a big pharmaceutical company's R&D systems landscape. By looking at this portfolio of systems they can all be considered components of a larger system, the "R&D IT System", supporting different parts of the processes being used in R&D.
In order to maximise the benefits that can be had by the amount of money the organization can afford to spend on IT, an overview of all these systems has to be established and their development coordinated. This gives the basis for assessing what specific benefits each component can give, and thereby the allocation of project funds.
On 7 February 2006, at NNIT's eClinical Conference in Copenhagen, this topic will be explored further by thought-leaders from AstraZeneca, Novo Nordisk, Bristol-Myers Squibb, Bayer, Serono, H. Lundbeck, Solvay and Merck & Co. Mail apb@nnit.com to take part.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.